Europe - Frankfurt Stock Exchange - FRA:BRM - US1101221083 - Common Stock
Taking everything into account, BRM scores 6 out of 10 in our fundamental rating. BRM was compared to 55 industry peers in the Pharmaceuticals industry. BRM has an average financial health and profitability rating. BRM may be a bit undervalued, certainly considering the very reasonable score on growth BRM also has an excellent dividend rating. These ratings could make BRM a good candidate for value and dividend investing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 16.42% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.23 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.31 | ||
| Fwd PE | 8.98 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.25 | ||
| EV/EBITDA | 6.78 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.59% |
ChartMill assigns a fundamental rating of 6 / 10 to BRM.DE.
ChartMill assigns a valuation rating of 9 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 5 / 10.
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to grow by 471.99% in the next year.
The dividend rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 8 / 10 and the dividend payout ratio is 82.81%.